Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy - Trial NCT06413043
Access comprehensive clinical trial information for NCT06413043 through Pure Global AI's free database. This phase not specified trial is sponsored by All India Institute of Medical Sciences, Bhubaneswar and is currently Not yet recruiting. The study focuses on Thyroid Eye Disease,Graves Ophthalmopathy. Target enrollment is 78 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
All India Institute of Medical Sciences, Bhubaneswar
Timeline & Enrollment
N/A
May 06, 2024
Nov 05, 2025
Primary Outcome
To evaluate and compare the response of add on selenium in patients with grave's ophthalmopathy
Summary
The Study on efficacy of add on selenium in mild-to-moderate Graves ophthalmopathy: A
 Randomized Control Trial.; The study aims to evaluate the response of adding selenium in
 patients with Graves ophthalmopathy, focusing on improving quality of life, CAS scoring, and
 thyroid status. The methodology involves a Randomized Control Trial with a sample size of 78
 patients. Patients meeting specific criteria will receive either standard treatment with Anti
 Thyroid Drugs and Vitamin B complex or add on selenium with Vitamin B complex for 6 months.
 Outcome measures include CAS score reduction, thyroid function improvement, and quality of
 life enhancement. The study will last 18 months, with various investigations and ethical
 considerations outlined. The document emphasizes the importance of early diagnosis of Graves
 Ophthalmopathy to prevent vision loss and deformity, highlighting the significance of
 informed patients and healthcare professionals regarding TED symptoms and risk factors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06413043
Non-Device Trial